Non-small Cell CarcinomaPhase 3NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
A Phase 3 study testing PF-08046054 and Docetaxel monotherapy in people with Non-small Cell Carcinoma and Non-Small Cell Lung Cancer Metastatic, run by Pfizer at 447 sites in 29 countries.
Trial summary
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
- What is being tested?
- PF-08046054 and Docetaxel monotherapy
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 680 participants
- Where
- 447 sitesin 29 countries
- Study dates
- 29 Sep 2025to 10 Mar 2032
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically or cytologically confirmed diagnosis of NSCLC with locally advanced, unresectable Stage IIIB or IIIC not eligible for definitive chemoradiotherapy or metastatic (Stage IV: M1a, M1b, or M1c) disease per the American Joint Committee on Cancer (AJCC) Staging Manual, Version 8.0, and the Union for International Cancer Control (UICC) Staging System. Note: Participants with a neuroendocrine component or histology are not eligible.
- PD-L1 expression on ≥1% of tumor cells based on local immunohistochemistry (IHC) testing with an assay utilizing the anti-PD-L1 monoclonal antibody clones 22C3 or SP263.
- Participants who have NSCLC with known AGAs are permitted.
- Able to provide any of the following tumor tissues for biomarker analysis:
- Archival specimen (preferably collected within 12 months after the last anticancer therapy) (see laboratory manual for details); or
- De novo biopsy from a tumor lesion, if medically feasible.
Show all 14Show fewer
- Participants must have received the following therapies and progressed during or relapsed after receiving their most recent prior therapy, or have been intolerant to their most recent therapy:
- Participants with no known AGAs must fulfill 1 of the following conditions:
- Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, and unless contraindicated, a PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).
- Experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting and received a PD-(L)1 monoclonal antibody at any time during the course of treatment.
- Participants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following conditions:
- Must have received at least 1 relevant AGA-targeted therapy if locally available and, in the opinion of the investigator, additional AGA-targeted therapy is not in the best interest of the participant
- Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting.
- May have received PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).
Who cannot join
- History of another malignancy within 3 years before the first dose of PF-08046054, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year overall survival [OS] ≥90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
- Any central nervous system (CNS) lesions, unless definitively treated with CNS-directed local therapy (surgery and/or radiotherapy). Participants with definitively treated brain metastases are eligible if they meet the following criteria:
- The participant is on a stable dose of ≤10 mg/day of prednisone or equivalent for at least >14 days prior to randomization (if requiring steroid treatment).
- No clinical or radiographic progression in the CNS following CNS-directed definitive radiotherapy and/or surgery.
- Time since CNS-directed treatment is ≥28 days prior to randomization.
- Participants with a history of leptomeningeal metastasis are excluded.
Show all 9Show fewer
- Prior treatment with an anti-PD-L1 agent (where indicated per protocol) within 5 half-lives.
- Previous receipt of an MMAE-containing agent or prior docetaxel.
- There are additional inclusion and exclusion criteria. The study center will determine if criteria for participations are met.
Trial locations and contacts
447 sites in 29 countries. Contact the study team or a site near you to ask about taking part.
447 sites in 29 countries
United States241 sites, 241 recruiting
- Recruiting
Texas Oncology - West Texas
Abilene, Texas, 79606
- Recruiting
Alabama Oncology, Shelby
Alabaster, Alabama, 35007
- Recruiting
Texas Oncology-Northeast Texas
Allen, Texas, 75013
- Recruiting
Texas Oncology-West Texas
Amarillo, Texas, 79124
- Recruiting
Alaska Oncology and Hematology
Anchorage, Alaska, 99508
- Recruiting
Maryland Oncology Hematology, P.A.
Annapolis, Maryland, 21401
- Recruiting
Texas Oncology - DFW
Arlington, Texas, 76012
- Recruiting
The Center for Cancer and Blood Disorders
Arlington, Texas, 76014
- Recruiting
Texas Oncology - DFW
Arlington, Texas, 76104
- Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois, 60005
- Recruiting
Rocky Mountain Cancer Centers LLP
Aurora, Colorado, 80012
- Recruiting
Texas Oncology- Central South.
Austin, Texas, 78705
- Recruiting
Texas Oncology Central South
Austin, Texas, 78731
- Recruiting
Texas Oncology- Central South.
Austin, Texas, 78745
- Recruiting
Texas Oncology - Central South (Renfert Way)
Austin, Texas, 78758
- Recruiting
University Hospitals Seidman Cancer Center at UH Avon Health Center
Avon, Ohio, 44011
- Recruiting
Baptist Cancer Center
Bartlett, Tennessee, 38133
- Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
- Recruiting
Texas Oncology - Gulf Coast
Beaumont, Texas, 77702
- Recruiting
OHSU Knight Cancer Institute, Beaverton
Beaverton, Oregon, 97006
- Recruiting
Texas Oncology - DFW
Bedford, Texas, 76022
- Recruiting
Essex Oncology of North Jersey
Belleville, New Jersey, 07109
- Recruiting
Nebraska Medicine-Bellevue Medical Center
Bellevue, Nebraska, 68123
- Recruiting
Alliance Cancer Specialists, PC
Bensalem, Pennsylvania, 19020
- Recruiting
Alta Bates Summit Medical Center Comprehensive Cancer Center
Berkeley, California, 94704
- Recruiting
Alabama Oncology, Bessemer
Bessemer, Alabama, 35022
- Recruiting
Maryland Oncology Hematology, P.A.
Bethesda, Maryland, 20817
- Recruiting
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
Billings, Montana, 59102
- Recruiting
Alabama Oncology, St Vincent's Birmingham
Birmingham, Alabama, 35205
- Recruiting
Alabama Oncology, Brookwood
Birmingham, Alabama, 35209
- Recruiting
Alabama Oncology, Princeton
Birmingham, Alabama, 35211
- Recruiting
University of Alabama at Birmingham
Birmingham, Alabama, 35233
- Recruiting
Alabama Oncology, St Vincent's East
Birmingham, Alabama, 35235
- Recruiting
Alabama Oncology, Grandview Cancer Center
Birmingham, Alabama, 35243
- Recruiting
University of Alabama at Birmingham, IDS Pharmacy
Birmingham, Alabama, 35249
- Recruiting
University of Alabama at Birmingham
Birmingham, Alabama, 35249
- Recruiting
Oncology & Hematology Associates of Southwest Virginia,Inc.DBA Blue Ridge Cancer Care
Blacksburg, Virginia, 24060
- Recruiting
Illinois CancerCare- Bloomington
Bloomington, Illinois, 61704
- Recruiting
Rocky Mountain Cancer Centers LLP
Boulder, Colorado, 80303
- Recruiting
Bozeman Health Deaconess Hospital - Bozeman Health Cancer Center
Bozeman, Montana, 59715
- Recruiting
Bozeman Health Deaconess Hospital - Bozeman Health Clinical Research
Bozeman, Montana, 59715
- Recruiting
Bozeman Health Deaconess Hospital
Bozeman, Montana, 59715
- Recruiting
Maryland Oncology Hematology, PA
Brandywine, Maryland, 20613
- Recruiting
Consultants in Medical Oncology and Hematology, P.C.
Broomall, Pennsylvania, 19008
- Recruiting
The Center for Cancer and Blood Disorders
Burleson, Texas, 76028
- Recruiting
Minnesota Oncology Hematology, PA
Burnsville, Minnesota, 55337
- Recruiting
Rocky Mountain Cancer Centers LLP
Centennial, Colorado, 80112
- Recruiting
Tennessee Oncology, PLLC - Chattanooga Downtown
Chattanooga, Tennessee, 37403
- Recruiting
Tennessee Oncology, PLLC - Chattanooga Med Park II
Chattanooga, Tennessee, 37404
- Recruiting
Tennessee Oncology, PLLC - Chattanooga Memorial
Chattanooga, Tennessee, 37404
- Recruiting
Tennessee Oncology, PLLC - Investigational Drug Services/Supply Storage
Chattanooga, Tennessee, 37404
- Recruiting
Illinois Cancer Specialists
Chicago, Illinois, 60631
- Recruiting
Oncology_Hematology Care Clinical Trials,LLC
Cincinnati, Ohio, 45211
- Recruiting
Oncology_Hematology Care Clinical Trials,LLC
Cincinnati, Ohio, 45242
- Recruiting
Oncology_Hematology Care Clinical Trials,LLC
Cincinnati, Ohio, 45245
- Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
- Recruiting
Tennessee Oncology, PLLC - Cleveland
Cleveland, Tennessee, 37311
- Recruiting
Baptist Cancer Center
Collierville, Tennessee, 38017
- Recruiting
Rocky Mountain Cancer Centers LLP
Colorado Springs, Colorado, 80907
- Recruiting
Rocky Mountain Cancer Centers LLP
Colorado Springs, Colorado, 80923
- Recruiting
Maryland Oncology Hematology
Columbia, Maryland, 21044
- Recruiting
Missouri Cancer Associates
Columbia, Missouri, 65201
- Recruiting
John Muir Health Clinical Research Center
Concord, California, 94520
- Recruiting
The University of Texas, MD Anderson Cancer Center - Woodlands
Conroe, Texas, 77384
- Recruiting
Allina Health Cancer Institute - Mercy Hospital
Coon Rapids, Minnesota, 55433
- Recruiting
Minnesota Oncology Hematology, PA
Coon Rapids, Minnesota, 55433
- Recruiting
Texas Oncology - DFW
Dallas, Texas, 75203
- Recruiting
Texas Oncology - DFW
Dallas, Texas, 75230
- Recruiting
Texas Oncology - DFW
Dallas, Texas, 75231
- Recruiting
Texas Oncology - DFW
Dallas, Texas, 75237
- Recruiting
Texas Oncology - DFW
Dallas, Texas, 75246
- Recruiting
Tennessee Oncology, PLLC - Dalton
Dalton, Georgia, 30720
- Recruiting
Southern Cancer Center
Daphne, Alabama, 36526
- Recruiting
Texas Oncology-Northeast Texas
Denison, Texas, 75020
- Recruiting
Texas Oncology-Northeast Texas
Denton, Texas, 76201
- Recruiting
Rocky Mountain Cancer Centers,LLP
Denver, Colorado, 80218
- Recruiting
Rocky Mountain Cancer Centers LLP
Denver, Colorado, 80220
- Recruiting
Alliance Cancer Specialists, PC
Doylestown, Pennsylvania, 18901
- Recruiting
Minnesota Oncology Hematology, P.A.
Edina, Minnesota, 55435
- Recruiting
Texas Oncology-West Texas
El Paso, Texas, 79902
- Recruiting
Texas Oncology-West Texas
El Paso, Texas, 79915
- Recruiting
Texas Oncology-West Texas
El Paso, Texas, 79938
- Recruiting
UC San Diego Medical Center - Encinitas
Encinitas, California, 92024
- Recruiting
Rocky Mountain Cancer Centers LLP
Englewood, Colorado, 80113
- Recruiting
Oncology Associates of Oregon, P.C.
Eugene, Oregon, 97401
- Recruiting
Oncology_Hematology Care Clinical Trials,LLC
Fairfield, Ohio, 45014
- Recruiting
Highlands Oncology Group, PA
Fayetteville, Arkansas, 72703
- Recruiting
Texas Oncology-Northeast Texas
Flower Mound, Texas, 75028
- Recruiting
Southern Cancer Center, PC
Foley, Alabama, 36535
- Recruiting
Texas Oncology - DFW
Fort Worth, Texas, 76104
- Recruiting
The Center for Cancer and Blood Disorders
Fort Worth, Texas, 76104
- Recruiting
Providence Medical Foundation
Fullerton, California, 92835
- Recruiting
Providence St. Jude Medical Center
Fullerton, California, 92835
- Recruiting
Illinois CancerCare Galesburg
Galesburg, Illinois, 61401
- Recruiting
Maryland Oncology Hematology P.A.
Germantown, Maryland, 20876
- Recruiting
The West Clinic PC dba West Cancer Center
Germantown, Tennessee, 38138
- Recruiting
Texas Oncology - DFW
Grapevine, Texas, 76051
- Recruiting
OHSU Knight Cancer Institute, Gresham
Gresham, Oregon, 97030
- Recruiting
Texas Oncology- Central South
Harlingen, Texas, 78550
- Recruiting
Alliance Cancer Specialists, PC
Horsham, Pennsylvania, 19044
- Recruiting
Texas Oncology - Gulf Coast
Houston, Texas, 77024
- Recruiting
The University of Texas MD Anderson Cancer Center Diagnostic Imaging
Houston, Texas, 77030
- Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
- Recruiting
The University of Texas, MD Anderson Cancer Center- Interventional Radiology
Houston, Texas, 77030
- Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
- Recruiting
The University of Texas MD Anderson Cancer Center Clinical Research Imaging
Houston, Texas, 77054
- Recruiting
The University of Texas, MD Anderson Cancer Center - West Houston
Houston, Texas, 77079
- Recruiting
Texas Oncology - Gulf Coast
Humble, Texas, 77338
- Recruiting
US Oncology Investigational Product Center (IPC)
Irving, Texas, 75063
- Recruiting
US Oncology Investigational Products Center (IPC)
Irving, Texas, 75063
- Recruiting
US Oncology Investigational Products Center(IPC)
Irving, Texas, 75063
- Recruiting
Tennessee Cancer Specialists
Knoxville, Tennessee, 37909
- Recruiting
Tennessee Cancer Specialists - Parkwest Location
Knoxville, Tennessee, 37932
- Recruiting
UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Pavilion
La Jolla, California, 92037
- Recruiting
UC San Diego Moores Cancer Center
La Jolla, California, 92037
- Recruiting
UCSD Koman Family Outpatient Pavilion
La Jolla, California, 92037
- Recruiting
Rocky Mountain Cancer Centers LLP
Lakewood, Colorado, 80228
- Recruiting
Alliance Cancer Specialists, P.C.
Langhorne, Pennsylvania, 19047
- Recruiting
Maryland Oncology Hematology, P.A
Largo, Maryland, 20774
- Recruiting
The University of Texas, MD Anderson Cancer Center - League City
League City, Texas, 77573
- Recruiting
Tennessee Oncology, PLLC - Lebanon
Lebanon, Tennessee, 37090
- Recruiting
Texas Oncology-Northeast Texas
Lewisville, Texas, 75056
- Recruiting
Accellacare of Duly
Lisle, Illinois, 60532
- Recruiting
Rocky Mountain Cancer Centers LLP
Littleton, Colorado, 80120
- Recruiting
Rocky Mountain Cancer Centers LLP
Lone Tree, Colorado, 80124
- Recruiting
Rocky Mountain Cancer Centers LLP
Longmont, Colorado, 80504
- Recruiting
Texas Oncology-Northeast Texas
Longview, Texas, 75601
- Recruiting
Norton Cancer Institute Downtown
Louisville, Kentucky, 40202
- Recruiting
Norton Cancer Institute, Downtown
Louisville, Kentucky, 40202
- Recruiting
Norton Hospital
Louisville, Kentucky, 40202
- Recruiting
Norton Audubon Hospital
Louisville, Kentucky, 40217
- Recruiting
Norton Cancer Institute, Audubon Hospital Campus
Louisville, Kentucky, 40217
- Recruiting
Norton Brownsboro Hospital
Louisville, Kentucky, 40241
- Recruiting
Norton Cancer Institute, Brownsboro Hospital Campus
Louisville, Kentucky, 40241
- Recruiting
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer care| Emmett Medical & Surgical Center
Low Moor, Virginia, 24457
- Recruiting
Covenant Children's Hospital- Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410
- Recruiting
Minnesota Oncology Hematology PA
Maple Grove, Minnesota, 55369
- Recruiting
Minnesota Oncology Hematology, P.A.
Maplewood, Minnesota, 55109
- Recruiting
Texas Oncology -Central South
McAllen, Texas, 78503
- Recruiting
Texas Oncology-Northeast Texas
McKinney, Texas, 75071
- Recruiting
Alliance Cancer Specialists, PC
Media, Pennsylvania, 19063
- Recruiting
Baptist Cancer Center
Memphis, Tennessee, 38120
- Recruiting
Baptist Clinical Research Institute
Memphis, Tennessee, 38120
- Recruiting
University Hospitals Seidman Cancer Center at UH Mentor Health Center
Mentor, Ohio, 44060
- Recruiting
Texas Oncology-West Texas
Midland, Texas, 79701
- Recruiting
Minnesota Oncology Hematology, P.A...
Minneapolis, Minnesota, 55404
- Recruiting
Allina Health Cancer Institute - Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407
- Recruiting
Tennessee Oncology, PLLC - Mount Juliet
Mount Juliet, Tennessee, 37122
- Recruiting
Tennessee Oncology, PLLC - Murfreesboro
Murfreesboro, Tennessee, 37129
- Recruiting
SCRI Oncology Partners
Nashville, Tennessee, 37203
- Recruiting
Tennessee Oncology, PLLC - Investigational Drug Services
Nashville, Tennessee, 37203
- Recruiting
Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic
Nashville, Tennessee, 37203
- Recruiting
Tennessee Oncology, PLLC - Nashville Saint Thomas West
Nashville, Tennessee, 37205
- Recruiting
Medical Oncology Hematology Consultants, PA
Newark, Delaware, 19713
- Recruiting
Texas Oncology-West Texas
Odessa, Texas, 79761
- Recruiting
American Oncology Network Vista Oncology Division-West office
Olympia, Washington, 98502
- Recruiting
American Oncology Network Vista Oncology Division-East office
Olympia, Washington, 98506
- Recruiting
Nebraska Medicine
Omaha, Nebraska, 68105
- Recruiting
Nebraska Medicine - Village Pointe
Omaha, Nebraska, 68118
- Recruiting
University Of Nebraska Medical Center
Omaha, Nebraska, 68198
- Recruiting
UH Minoff Health Center at Chagrin Highlands
Orange, Ohio, 44122
- Recruiting
Illinois CancerCare-Ottawa-Fox River Cancer Center
Ottawa, Illinois, 61350
- Recruiting
Texas Oncology-Northeast Texas
Palestine, Texas, 75801
- Recruiting
Cancer Care Centers of Brevard, Inc.
Palm Bay, Florida, 32901
- Recruiting
Florida Cancer Affiliates - Panama City
Panama City, Florida, 32405
- Recruiting
Texas Oncology-Northeast Texas
Paris, Texas, 75460
- Recruiting
Texas Oncology - Gulf Coast
Pearland, Texas, 77584
- Recruiting
Illinois CancerCare- Pekin
Pekin, Illinois, 61554
- Recruiting
Illinois Cancer Care
Peoria, Illinois, 61615
- Recruiting
Illinois CancerCare-Peru - Valley Regional Cancer Center
Peru, Illinois, 61354
- Recruiting
Texas Oncology - DFW
Plano, Texas, 75075
- Recruiting
Texas Oncology - DFW
Plano, Texas, 75093
- Recruiting
OHSU Knight Cancer Institute, Northwest
Portland, Oregon, 97210
- Recruiting
Providence Cancer Institute Franz Clinic
Portland, Oregon, 97213
- Recruiting
OHSU Knight Cancer Institute, East Portland
Portland, Oregon, 97216
- Recruiting
Providence Investigational Drug Service - Westside
Portland, Oregon, 97225
- Recruiting
Providence Oncology and Hematology Care -Westside
Portland, Oregon, 97225
- Recruiting
OHSU Research Pharmacy Services, CHH2
Portland, Oregon, 97239
- Recruiting
Oregon Health and Science University, CHH1
Portland, Oregon, 97239
- Recruiting
Oregon Health and Science University, CHH2
Portland, Oregon, 97239
- Recruiting
Oregon Health and Science University
Portland, Oregon, 97239
- Recruiting
Rocky Mountain Cancer Centers LLP
Pueblo, Colorado, 81003
- Recruiting
VCU Emergency Center at New Kent
Quinton, Virginia, 23141
- Recruiting
Renown Health Medical Oncology
Reno, Nevada, 89502
- Recruiting
Renown Office of Clinical Research
Reno, Nevada, 89502
- Recruiting
Renown Regional Medical Center
Reno, Nevada, 89502
- Recruiting
VCU Medical Center Gateway Building
Richmond, Virginia, 23219
- Recruiting
Virginia Commonwealth University
Richmond, Virginia, 23219
- Recruiting
VCU Health Short Pump Pavilion
Richmond, Virginia, 23233
- Recruiting
VCU Health Stony Point
Richmond, Virginia, 23235
- Recruiting
Massey Cancer Center Clinical & Translational Research Lab
Richmond, Virginia, 23298
- Recruiting
Virginia Commonwealth University
Richmond, Virginia, 23298
- Recruiting
Tennessee Oncology, PLLC - Ringgold
Ringgold, Georgia, 30736
- Recruiting
Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care
Roanoke, Virginia, 24014
- Recruiting
Maryland Oncology Hematology PA
Rockville, Maryland, 20850
- Recruiting
Highlands Oncology Group, PA
Rogers, Arkansas, 72758
- Recruiting
Roseville Medical Plaza Care Center
Roseville, California, 95661
- Recruiting
Sutter Medical Center, Sacramento Infusion Center at Roseville
Roseville, California, 95661
- Recruiting
Baylor Scott & White Health - Round Rock
Round Rock, Texas, 78665
- Recruiting
Buhler Specialty Pavilion
Sacramento, California, 95816
- Recruiting
Sutter Medical Center, Sacramento Infusion Center
Sacramento, California, 95816
- Recruiting
Allina Health Cancer Institute - United Hospital
Saint Paul, Minnesota, 55102
- Recruiting
Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care
Salem, Virginia, 24153
- Recruiting
UC San Diego McGrath Outpatient Pavilion - Hillcrest
San Diego, California, 92103
- Recruiting
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103
- Recruiting
UCSD Medical Center - Rancho Bernardo
San Diego, California, 92127
- Recruiting
CHRISTUS St. Vincent Regional Cancer Center
Santa Fe, New Mexico, 87505
- Recruiting
Christus St. Vincent Regional Medical Center
Santa Fe, New Mexico, 87505
- Recruiting
Alliance Cancer Specialists, PC
Sellersville, Pennsylvania, 18960
- Recruiting
Tennessee Oncology, PLLC - Shelbyville
Shelbyville, Tennessee, 37160
- Recruiting
Maryland Oncology Hematology, P.A.
Silver Spring, Maryland, 20904
- Recruiting
Tennessee Oncology, PLLC - Smyrna
Smyrna, Tennessee, 37167
- Recruiting
VCU Health Community Memorial Hospital
South Hill, Virginia, 23970
- Recruiting
Baptist Cancer Center
Southaven, Mississippi, 38671
- Recruiting
Highlands Oncology Group, PA
Springdale, Arkansas, 72762
- Recruiting
Highlands Oncology Group
Springdale, Arkansas, 72762
- Recruiting
The University of Texas, MD Anderson Cancer Center - Sugar Land
Sugar Land, Texas, 77478
- Recruiting
Texas Oncology - Gulf Coast
Sugar Land, Texas, 77479
- Recruiting
VCU Health Tappahannock Hospital
Tappahannock, Virginia, 22560
- Recruiting
Montefiore Medical Center - Montefiore Medical Park
The Bronx, New York, 10461
- Recruiting
Texas Oncology - Gulf Coast
The Woodlands, Texas, 77380
- Recruiting
Rocky Mountain Cancer Centers LLP
Thornton, Colorado, 80260
- Recruiting
OHSU Knight Cancer Institute, Tualatin
Tualatin, Oregon, 97062
- Recruiting
Texas Oncology-Northeast Texas
Tyler, Texas, 75702
- Recruiting
UC San Diego Medical Center - Vista
Vista, California, 92081
- Recruiting
Texas Oncology- Central South
Waco, Texas, 76712
- Recruiting
Texas Oncology-Central South
Waco, Texas, 76712
- Recruiting
John Muir Health Cancer Center
Walnut Creek, California, 94598
- Recruiting
John Muir Health Clinical Research Center
Walnut Creek, California, 94598
- Recruiting
John Muir Medical Center - Walnut Creek Campus
Walnut Creek, California, 94598
- Recruiting
Illinois CancerCare - Washington
Washington, Illinois, 61571
- Recruiting
The Center for Cancer and Blood Disorders
Weatherford, Texas, 76086
- Recruiting
Texas Oncology - Gulf Coast
Webster, Texas, 77598
- Recruiting
Texas Oncology - Central South
Weslaco, Texas, 78596
- Recruiting
White Plains Hospital
White Plains, New York, 10601
- Recruiting
Texas Oncology-West Texas
Wichita Falls, Texas, 76310
- Recruiting
Shenandoah Oncology, P.C.
Winchester, Virginia, 22601
- Recruiting
Minnesota Oncology Hematology, PA
Woodbury, Minnesota, 55125
- Recruiting
University of Massachusetts Worcester
Worcester, Massachusetts, 01655
- Recruiting
Alliance Cancer Specialists, PC
Wynnewood, Pennsylvania, 19096
- Recruiting
Oncology & Hematology Associates of Southwest Virginia, Inc.,DBA Blue Ridge Cancer Care
Wytheville, Virginia, 24382
China24 sites, 24 recruiting
- Not yet recruiting
Beijing Friendship Hospital Affiliate of Capital University
Beijing, Beijing Municipality, 100050
- Recruiting
Beijing Cancer hospital
Beijing, Beijing Municipality, 100142
- Recruiting
Hunan Cancer Hospital
Changsha, Hunan, 410013
- Recruiting
The First People's Hospital of Changzhou
Changzhou, Jiangsu, 213003
- Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041
- Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030
- Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, 350014
- Recruiting
Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, 510515
- Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022
- Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081
- Recruiting
Anhui Provincial Hospital
Hefei, Anhui, 230001
- Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022
- Recruiting
Jinan Central Hospital
Jinan, Shandong, 250013
- Recruiting
Yunnan Province Cancer Hospital
Kunming, Yunnan, 650118
- Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330209
- Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029
- Recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, 530021
- Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032
- Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200123
- Recruiting
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, 317000
- Recruiting
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430030
- Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061
- Recruiting
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, Jiangsu, 221006
- Recruiting
Henan Cancer Hospital
Zhengzhou, 450008
Japan19 sites, 19 recruiting
- Not yet recruiting
Hyogo Cancer Center
Akashi, Hyōgo, 673-8558
- Recruiting
National Hospital Organization Beppu Medical Center
Beppu-shi, Oita Prefecture, 874-0011
- Recruiting
Nippon Medical School Hospital
Bunkyo-ku, Tokyo, 113-8603
- Recruiting
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395
- Not yet recruiting
National Hospital Organization Tokyo National Hospital
Kiyose, Tokyo, 204-8585
- Recruiting
National Hospital Organization Kochi National Hospital
Kochi, Kochi, 780-8077
- Recruiting
National Hospital Organization Kure Medical Center and Chugoku Cancer Center
Kure, Hiroshima, 737-0023
- Recruiting
Kurume University Hospital
Kurume, Fukuoka, 830-0011
- Recruiting
National Hospital Organization Kyoto Medical Center
Kyoto, 612-8555
- Recruiting
Shizuoka Cancer Center
Nagaizumi-cho, Shizuoka, 411-8777
- Recruiting
National Hospital Organization Okayama Medical Center
Okayama, 701-1192
- Recruiting
National Hospital Organization Nagasaki Medical Center
Ōmura, Nagasaki, 856-8562
- Recruiting
Osaka International Cancer Institute
Osaka, 541-8567
- Recruiting
Kindai University Hospital
Sakai, Osaka, 590-0197
- Not yet recruiting
NHO Kinki Chuo Chest Medical Center
Sakai, Osaka, 591-8555
- Recruiting
Sendai Kousei Hospital
Sendai, Miyagi, 9810914
- Recruiting
Osaka University Hospital
Suita, Osaka, 565-0871
- Recruiting
The University of Osaka Hospital
Suita, Osaka, 565-0871
- Recruiting
Mie Chuo Medical Center
Tsu, Mie-ken, 514-1101
Germany15 sites, 15 recruiting
- Recruiting
Zentralklinik Bad Berka GmbH
Bad Berka, 99437
- Recruiting
Vivantes Auguste-Viktoria-Klinikum
Berlin, 12157
- Recruiting
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, 53127
- Recruiting
Universitaetsklinikum Essen West German Cancer Center
Essen, 45147
- Recruiting
Krankenhaus Nordwest GmbH
Frankfurt am Main, Hesse, D-60488
- Recruiting
UKGM Gießen/Marburg
Giessen, Hesse, 35392
- Recruiting
LungenClinic Grosshansdorf
Großhansdorf, Schleswig-Holstein, 22927
- Recruiting
Thoraxklinik-Heidelberg gGmbH
Heidelberg, Baden-Wurttemberg, 69126
- Recruiting
MVZ am Klinikum Aschaffenburg
Hösbach, Bavaria, 63768
- Recruiting
Lungenfachklinik Immenhausen
Immenhausen, Hesse, 34376
- Recruiting
Universitaetsklinikum Jena
Jena, 07747
- Recruiting
Klinikum Kassel GmbH
Kassel, Hesse, 34125
- Recruiting
InVO Institut für Versorgungsforschung in der Onkologie
Koblenz, Rhineland-Palatinate, 56068
- Recruiting
Central Apotheke
Steinbach, 61449
- Recruiting
Robert-Bosch-Krankenhaus
Stuttgart, Baden-Wurttemberg, 70376
Spain14 sites, 14 recruiting
- Recruiting
CHUAC-Complejo Hospitalario Universitario A Coruña
A Coruña, A Coruña [LA Coruña], 15006
- Recruiting
Hospital Universitario de Badajoz
Badajoz, 06006
- Recruiting
Institut Català d'Oncologia (ICO) - Badalona
Badalona, Barcelona [barcelona], 08916
- Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], 08035
- Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalunya [cataluña], 08041
- Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, 08025
- Recruiting
Hospital Universitario San Cecilio
Granada, 18016
- Recruiting
Hospital General Universitario Gregorio Marañon
Madrid, Madrid, Comunidad de, 28009
- Recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Comunidad de, 28041
- Recruiting
Hospital Universitari Son Espases
Palma, 07120
- Recruiting
Hospital Universitario Virgen de Valme
Seville, 41014
- Recruiting
Hospital General Universitario de Valencia
Valencia, 46014
- Recruiting
Hospital Universitari i Politecnic La Fe
Valencia, 46026
- Recruiting
Hospital Clínico Universitario Lozano Blesa
Zaragoza, 50009
France11 sites, 11 recruiting
- Recruiting
Institut Bergonié
Bordeaux, 33076
- Recruiting
Centre Hospitalier Universitaire Cavale Blanche
Brest, Brittany Region, 29200
- Recruiting
CHU Lille - Institut Coeur Poumon
Lille, NORD, 59037
- Recruiting
Assistance Publique Hôpitaux de Marseille - Hôpital Nord
Marseille, 13915
- Recruiting
Hopital Cochin
Paris, 75014
- Recruiting
Institut Curie
Paris, 75248
- Recruiting
Hôpital Tenon
Paris, 75970
- Recruiting
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
Rennes, Ille-et-vilaine, 35033
- Recruiting
Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes
Saint-Herblain, Loire-atlantique, 44800
- Recruiting
CHU de Toulouse - Hopital Larrey
Toulouse, Haute-garonne, 31059
- Recruiting
Gustave Roussy
Villejuif, Val-de-marne, 94805
Italy11 sites, 11 recruiting
- Recruiting
Cro-Irccs
Aviano, Pordenone, 33081
- Recruiting
Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni
Bergamo, 24125
- Recruiting
AORN Sant'Anna e San Sebastiano
Caserta, 81100
- Recruiting
Azienda Ospedaliera Universitaria Careggi
Florence, Tuscany, 50134
- Recruiting
IRCCS Azienda Ospedaliera Metropolitana (AOM)
Genova, 16132
- Recruiting
Ospedale San Raffaele
Milan, 20132
- Recruiting
Istituto Europeo di Oncologia IRCCS
Milan, 20141
- Recruiting
Ausl Della Romagna- Ospedale Santa Maria Delle Croci Ravenna
Ravenna, 48121
- Recruiting
Ospedale Isola Tiberina Gemelli Isola
Roma, ROME, 00186
- Recruiting
Istituto Nazionale Tumori Regina Elena
Rome, ROMA, 00144
- Recruiting
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
Verona, Veneto, 37126
South Korea11 sites, 11 recruiting
- Recruiting
Chungbuk National University Hospital
Cheongju-si, Chungcheongbuk-do [chungbuk], 28644
- Recruiting
Boramae Medical Center
Dongjak-gu, Seoul-teukbyeolsi [seoul], 07061
- Recruiting
National Cancer Center
Goyang-si, Kyǒnggi-do, 10408
- Recruiting
Inje University Haeundae Paik Hospital
Haeundae-gu, Pusan-kwangyǒkshi, 48108
- Recruiting
Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, 13620
- Recruiting
CHA Bundang Medical Center, CHA University
Seongnam-si, Kyǒnggi-do, 13496
- Recruiting
Severance Hospital, Yonsei University Health System
Seoul, Seoul-teukbyeolsi [seoul], 03722
- Recruiting
Asan Medical Center
Seoul, Seoul-teukbyeolsi [seoul], 05505
- Recruiting
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [seoul], 06351
- Recruiting
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, Seoul-teukbyeolsi [seoul], 06591
- Recruiting
The Catholic University Of Korea St. Vincent's Hospital
Suwon, Kyǒnggi-do, 16247
Canada10 sites, 10 recruiting
- Recruiting
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
- Recruiting
Sante Quebec Monteregie-Centre
Greenfield Park, Quebec, J4V2H1
- Recruiting
Sante Quebec Laval, Hopital de la Cite-de-la-Sante
Laval, Quebec, H7M 3L9
- Recruiting
McGill University Health Centre
Montreal, Quebec, H4A 3J1
- Recruiting
Lakeridge Health
Oshawa, Ontario, L1G 2B9
- Recruiting
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus
Québec, G1J 1Z4
- Recruiting
IUCPQ-Universite Laval
Québec, G1V 4G5
- Recruiting
Centre de Services Ambulatoire de St-Jerome
Saint-Jérôme, Quebec, J7Y 0L1
- Recruiting
Unité de Recherche Clinique du CISSS des Laurentides
Saint-Jérôme, Quebec, J7Z 2V4
- Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9
Greece8 sites, 8 recruiting
- Recruiting
Thoracic General Hospital of Athens "I Sotiria"
Athens, Attikí, 115 27
- Recruiting
?enry Dunant Hospital Center Fourth Department of Oncology and Clinical Trials Unit
Athens, 115 26
- Recruiting
University General Hospital of Heraklion
Heraklion, Irakleío, 715 00
- Recruiting
University General Hospital of Heraklion
Irakleio, Irakleío, 71110
- Recruiting
University General Hospital of Larissa
Larissa, Thessalía, 41110
- Recruiting
Metropolitan Hospital
Piraeus, Attikí, 185 47
- Recruiting
Agios Loukas Clinic
Thessaloniki, Thessaloníki, 552 36
- Recruiting
European Interbalkan Medical Center
Thessaloniki, Thessaloníki, 570 01
Argentina7 sites, 7 recruiting
- Recruiting
Instituto Argentino de Diagnóstico y Tratamiento (IADT)
Buenos Aires, C1122AAL
- Recruiting
Fundación Respirar
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ABP
- Recruiting
Hospital Privado Universitario de Córdoba
Córdoba, 5016
- Recruiting
Centro de Investigaciones Oncológicas Colon
Mar del Plata, 7600
- Recruiting
Sanatorio Parque
Rosario, Santa Fe Province, 2000
- Recruiting
Sanatorio Británico
Rosario, Santa Fe Province, S2000CVB
- Recruiting
COE (Centro Oncológico de Excelencia)
San Juan, 5400
Czechia6 sites, 6 recruiting
- Recruiting
Fakultní nemocnice Brno Bohunice Klinika nemocí plicních a tuberkulózy
Brno, 625 00
- Recruiting
Nemocnice AGEL Novy Jicin a.s.
Nový Jičín, 741 01
- Recruiting
Fakultni nemocnice Olomouc
Olomouc, 779 00
- Recruiting
Nemocnice AGEL Ostrava - Vítkovice a.s. Plicní ambulance - pneumoonkologická ambulance
Ostrava, Ostrava Město, 703 00
- Recruiting
Vseobecna fakultni nemocnice v Praze (Onkologicka klinika)
Prague, 128 08
- Recruiting
Fakultni nemocnice Motol a Homolka
Prague, 15006.
India6 sites, 6 recruiting
- Recruiting
Fortis Hospital
Delhi, 110088
- Recruiting
Caritas Hospital
Kerala, 686630
- Recruiting
Apollo Multispeciality Hospitals limited
Kolkata, West Bengal, 700054
- Recruiting
Tata Memorial Hospital
Mumbai, Maharashtra, 400012
- Recruiting
Rajiv Gandhi Cancer Institute And Research Centre
New Delhi, National Capital Territory of Delhi, 110085
- Recruiting
Sahyadri Super Speciality Hospital
Pune, Maharashtra, 411004
Israel6 sites, 6 recruiting
- Recruiting
Shaare Zedek Medical Center
Jerusalem, Jerusalem, 9013102
- Recruiting
Hadassah Medical Center
Jerusalem, Jerusalem, 9112001
- Recruiting
Rabin Medical Center
Petah Tikva, Central District, 4941492
- Not yet recruiting
Sheba Medical Center
Ramat Gan, Central District, 5265601
- Recruiting
Sourasky Medical Center
Tel Aviv, TELL ABĪB, 6423906
- Recruiting
Yitzhak Shamir Medical Center
Ẕerifin, Central District, 70300
Taiwan6 sites, 6 recruiting
- Recruiting
Changhua Christian Hospital
Changhua County, Changhua, 50006
- Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
- Recruiting
Taichung Veterans General Hospital
Taichung, 407219
- Recruiting
National Cheng Kung University Hospital
Tainan, 704
- Recruiting
National Taiwan University Hospital
Taipei, 10002
- Recruiting
Taipei Veterans General Hospital
Taipei, 11217
Belgium5 sites, 5 recruiting
- Recruiting
Algemeen Ziekenhuis klina
Brasschaat, 2930
- Recruiting
Grand Hôpital de Charleroi -
Charleroi, Hainaut, 6060
- Recruiting
Jessa Ziekenhuis
Hasselt, Limburg, 3500
- Recruiting
Jessa Ziekenhuis
Hasselt, 3500
- Recruiting
AZ Sint-Maarten
Mechelen, Antwerpen, 2800
Brazil5 sites, 5 recruiting
- Recruiting
Hospital Santo Antonio
Blumenau, Santa Catarina, 89015-200
- Recruiting
Hospital de Clínicas de Passo Fundo
Passo Fundo, Rio Grande do Sul, 99010-260
- Recruiting
IBCC - Instituto Brasileiro de Controle do Câncer
São Paulo, 03102-002
- Recruiting
IBCC - Núcleo de Pesquisa e Ensino
São Paulo, 04014-002
- Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, 05652-900
Denmark5 sites, 5 recruiting
- Recruiting
Aarhus University Hospital
Aarhus N, 8200
- Recruiting
Rigshospitalet Department of Oncology
Copenhagen, Capital Region, 2100
- Recruiting
Herlev and Gentofte Hospital
Copenhagen, Capital Region, 2730
- Recruiting
Odense Universitetshospital
Odense, Region Syddanmark, 5000
- Recruiting
Roskilde Sygehus
Roskilde, Region Sjælland, 4000
Australia4 sites, 4 recruiting
- Recruiting
Grampians Health
Ballarat, Victoria, 3350
- Recruiting
Royal Hobart Hospital
Hobart, Tasmania, 7000
- Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, 2298
- Recruiting
Westmead Hospital
Westmead, New South Wales, 2145
Bulgaria4 sites, 4 recruiting
- Not yet recruiting
Specialized Hospital for Active Treatment of Oncology - Haskovo
Haskovo, 6300
- Not yet recruiting
MBAL Uni Hospital
Panagyurishte, Pazardzhik, 4500
- Recruiting
MHAT for Women's Health Nadezhda
Sofia, 1330
- Not yet recruiting
Trakia Hospital
Stara Zagora, 6000
Finland4 sites, 4 recruiting
- Recruiting
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus)
Helsinki, Uusimaa, 00029
- Recruiting
Kuopion Yliopistollinen Sairaala
Kuopio, Northern Savonia, 70210
- Recruiting
Turku University Hospital
Turku, Southwest Finland, 20521
- Not yet recruiting
Vaasan Keskussairaala
Vaasa, Pohjanmaa, 65130
Netherlands4 sites, 4 recruiting
- Recruiting
Amsterdam UMC, locatie VUmc
Amsterdam, North Holland, 1081 HV
- Recruiting
Maastricht UMC+
Maastricht, Limburg, 6229 HX
- Recruiting
Erasmus Medisch Centrum
Rotterdam, South Holland, 3015 GD
- Recruiting
St. Antonius Ziekenhuis, locatie Utrecht
Utrecht, 3543 AZ
Poland4 sites, 4 recruiting
- Recruiting
Instytut MSF Sp zoo
Lodz, Łódź Voivodeship, 90-302
- Recruiting
Instytut Genetyki i Immunologii GENIM
Lublin, Lublin Voivodeship, 20-609
- Not yet recruiting
Uniwersytecki Szpital Kliniczny w Poznaniu
Poznan, 60-569
- Not yet recruiting
Provita Centrum Medyczne Spółka Z Ograniczoną Odpowiedzialnością, Provita Prolife
Tomaszów Mazowiecki, 97-200
Slovakia4 sites, 4 recruiting
- Recruiting
Univerzitna nemocnica Bratislava, Nemocnica Ruzinov
Bratislava, 826 06
- Recruiting
Narodny onkologicky ustav
Bratislava, 833 10
- Recruiting
Nemocnica s poliklinikou Stefana Kukuru Michalovce, a.s.
Michalovce, 07101
- Recruiting
Fakultna nemocnica s poliklinikou Nove Zamky
Nové Zámky, 940 34
United Kingdom4 sites, 4 recruiting
- Recruiting
St Bartholomew's Hospital
London, London, CITY of, EC1A 7BE
- Recruiting
Sarah Cannon Research Institute UK
London, London, CITY of, w1g 6ad
- Recruiting
Barts Health NHS Trust , The Royal London Hospital
London, E1 1FR
- Recruiting
The Christie NHS Foundation Trust
Manchester, M20 4BX
Mexico3 sites, 3 recruiting
- Recruiting
Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"
Guadalajara, Jalisco, 44280
- Recruiting
Centro de Investigacion Clinica de Oaxaca
Oaxaca City, Oaxaca, 68020
- Recruiting
Clinica Integral Internacional de Oncolgia S. de R.L. de C.V ú Oncocenter
Puebla City, 72530
Sweden3 sites, 3 recruiting
- Recruiting
Mälarsjukhuset
Eskilstuna, Södermanlands LÄN [se-04], 631 88
- Recruiting
Sjukhuset I Gävle
Gävle, Gävleborgs LÄN [se-21], 80187
- Recruiting
Sahlgrenska Universitetssjukhuset
Gothenburg, Västra Götalands LÄN [se-14], 413 45
South Africa2 sites, 2 recruiting
- Recruiting
The Oncology Centre
Durban, KwaZulu-Natal, 4091
- Recruiting
The Medical Oncology Centre of Rosebank
Johannesburg, Gauteng, 2196
Puerto Rico1 site, 1 recruiting
- Recruiting
Ad-Vance Medical Research
Ponce, 00717
About this study
Official title: PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation.
Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.
- Conditions
- Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
- Being tested
- PF-08046054, Docetaxel monotherapy
- Keywords
- Non-small cell lung cancer NSCLC, NSCLC
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PF-08046054Drug
Also called SGN-PDL1V
Antibody Drug Conjugate
Participants will receive PF-08046054, administered as an IV infusion.
Docetaxel monotherapyDrug
Participants will receive Docetaxel, administered as an IV infusion.
| Study group | Role | What they receive |
|---|---|---|
| PF-08046054 monotherapy | Experimental | PF-08046054 monotherapy Receives: Drug: PF-08046054 |
| Docetaxel monotherapy | Active comparator | Docetaxel monotherapy Receives: Drug: Docetaxel monotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Overall survival defined as the time from the date of randomization to the date of death due to any cause.
Measured: Approximately 5 years
Secondary outcomes (15)
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
Progression-free survival is defined as the time from the date of randomization to the date of the first documentation of objective PD assessed by BICR per RECIST v1.1, or death due to any cause, whichever occurs first.
Measured: Approximately 5 years
Objective Response Rate as assessed by BICR
The proportion of participants who have a confirmed CR or PR, as best overall response assessed by BICR as per RECIST 1.1.
Measured: Approximately 5 years
Progression Free Survival as assessed by Investigator
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of the first documentation of objective PD assessed by investigator per RECIST v1.1, or death due to any cause, whichever occurs first.
Measured: Approximately 5 years
Objective Response Rate (ORR) as assessed by Investigator
The proportion of participants who have a confirmed CR or PR, as best overall response assessed by investigator as per RECIST 1.1.
Measured: Approximately 5 years
Duration of Response as assessed by BICR
The time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of the first documentation of PD as determined by BICR assessment per RECIST v1.1, or death due to any cause, whichever occurs first.
Measured: Approximately 5 years
Duration of Response as assessed by Investigator
The time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of the first documentation of PD as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first.
Measured: Approximately 5 years
Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Measured: Through 90 days after the last study intervention; Approximately 5 years
Mean scores and Change from baseline in the global health status/quality of life (QoL) score on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 is a questionnaire for quantitative measure of health-related quality of life pertinent to participants with a broad range of cancers who are participating in international clinical trials.
Measured: Approximately 5 years
Mean scores and Change from baseline in physical functioning and role functioning scores on the EORTC QLQ-C30
The EORTC QLQ-C30 is a questionnaire for quantitative measure of health-related quality of life pertinent to participants with a broad range of cancers who are participating in international clinical trials.
Measured: Approximately 5 years
Mean scores and Change from Baseline in dyspnea, cough, and chest pain scores on the EORTC Quality of Life Cancer Questionnaire - Lung Cancer 13 QLQ-LC13
The EORTC QLQ-LC13 is a lung cancer specific module and consists of 13 item questionnaire assessing lung cancer-associated symptoms and treatment-related effects.
Measured: Approximately 5 years
Time to definitive deterioration (TTdD) in in the global health status/QoL score on the EORTC QLQ-C30
TTdD is defined as the time from date of randomization to first onset of Patient Reported Outcome (PRO) deterioration without subsequent recovery.
Measured: Approximately 5 years
TTdD in physical functioning and role functioning scores on the EORTC QLQ-C30
TTdD is defined as the time from date of randomization to first onset of Patient Reported Outcome (PRO) deterioration without subsequent recovery.
Measured: Approximately 5 years
TTdD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13
TTdD is defined as the time from date of randomization to first onset of Patient Reported Outcome (PRO) deterioration without subsequent recovery.
Measured: Approximately 5 years
Pharmacokinetics (PK): Plasma concentration of PF-08046054 and and its components
To characterize the pharmacokinetics (PK) of PF-08046054
Measured: Approximately 48 weeks
Incidence of Anti-Drug Antibody (ADA)
To characterize the immunogenicity of PF-08046054
Measured: Approximately 48 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2025
- Study start29 Sep 2025
- Primary completion10 Mar 2028 (estimated)
- Study completion10 Mar 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-small Cell CarcinomaStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 680 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07144280
- Sponsor's protocol ID
- C5851005
- Other IDs
- 2025-521281-97-00, 2025
- Status last verified
- Oct 2026
- First submitted
- 20 Aug 2025
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- ClinicalTrials.gov ID
- NCT07144280
- Acronym / sponsor ID
- C5851005
- Conditions
- Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
- Keywords
- Non-small cell lung cancer NSCLC, NSCLC
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 680 participants (estimated)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 29 Sep 2025 (actual)
- Primary completion
- 10 Mar 2028 (estimated)
- Study completion
- 10 Mar 2032 (estimated)
- First posted
- 27 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation.
Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PF-08046054 monotherapy | Experimental | Drug: PF-08046054PF-08046054 monotherapy |
| Docetaxel monotherapy | Active comparator | Drug: Docetaxel monotherapyDocetaxel monotherapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Histologically or cytologically confirmed diagnosis of NSCLC with locally advanced, unresectable Stage IIIB or IIIC not eligible for definitive chemoradiotherapy or metastatic (Stage IV: M1a, M1b, or M1c) disease per the American Joint Committee on Cancer (AJCC) Staging Manual, Version 8.0, and the Union for International Cancer Control (UICC) Staging System. Note: Participants with a neuroendocrine component or histology are not eligible.
- PD-L1 expression on ≥1% of tumor cells based on local immunohistochemistry (IHC) testing with an assay utilizing the anti-PD-L1 monoclonal antibody clones 22C3 or SP263.
- Participants who have NSCLC with known AGAs are permitted.
- Able to provide any of the following tumor tissues for biomarker analysis:
- Participants must have received the following therapies and progressed during or relapsed after receiving their most recent prior therapy, or have been intolerant to their most recent therapy:
Key exclusion criteria (9 listed)
- History of another malignancy within 3 years before the first dose of PF-08046054, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year overall survival [OS] ≥90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
- Any central nervous system (CNS) lesions, unless definitively treated with CNS-directed local therapy (surgery and/or radiotherapy). Participants with definitively treated brain metastases are eligible if they meet the following criteria:
- Participants with a history of leptomeningeal metastasis are excluded.
- Prior treatment with an anti-PD-L1 agent (where indicated per protocol) within 5 half-lives.
- Previous receipt of an MMAE-containing agent or prior docetaxel.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PF-08046054Also: SGN-PDL1VAntibody Drug Conjugate Participants will receive PF-08046054, administered as an IV infusion. | Drug | PF-08046054 monotherapy |
| Docetaxel monotherapyParticipants will receive Docetaxel, administered as an IV infusion. | Drug | Docetaxel monotherapy |
Primary outcome
Overall Survival
Time frame: Approximately 5 years
Overall survival defined as the time from the date of randomization to the date of death due to any cause.
15 secondary outcomes
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
Time frame: Approximately 5 years
Objective Response Rate as assessed by BICR
Time frame: Approximately 5 years
Progression Free Survival as assessed by Investigator
Time frame: Approximately 5 years
Objective Response Rate (ORR) as assessed by Investigator
Time frame: Approximately 5 years
Duration of Response as assessed by BICR
Time frame: Approximately 5 years
Duration of Response as assessed by Investigator
Time frame: Approximately 5 years
Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation
Time frame: Through 90 days after the last study intervention; Approximately 5 years
Mean scores and Change from baseline in the global health status/quality of life (QoL) score on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Time frame: Approximately 5 years
Mean scores and Change from baseline in physical functioning and role functioning scores on the EORTC QLQ-C30
Time frame: Approximately 5 years
Mean scores and Change from Baseline in dyspnea, cough, and chest pain scores on the EORTC Quality of Life Cancer Questionnaire - Lung Cancer 13 QLQ-LC13
Time frame: Approximately 5 years
Time to definitive deterioration (TTdD) in in the global health status/QoL score on the EORTC QLQ-C30
Time frame: Approximately 5 years
TTdD in physical functioning and role functioning scores on the EORTC QLQ-C30
Time frame: Approximately 5 years
TTdD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13
Time frame: Approximately 5 years
Pharmacokinetics (PK): Plasma concentration of PF-08046054 and and its components
Time frame: Approximately 48 weeks
Incidence of Anti-Drug Antibody (ADA)
Time frame: Approximately 48 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Non-small Cell Carcinoma
RecruitingPhase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung Cancer, NSCLC
RecruitingPhase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
RecruitingPhase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 1
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
Lung Cancer
RecruitingPhase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pfizer CT.gov Call Center study director
Pfizer
447 sites in 29 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing PF-08046054 and Docetaxel monotherapy in people with Non-small Cell Carcinoma and Non-Small Cell Lung Cancer Metastatic, run by Pfizer at 447 sites in 29 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 447 sites in United States, China, Japan, Germany, Spain and 24 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pfizer CT.gov Call Center (1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: Approximately 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026; AzTrials last refreshed its copy on 27 Oct 2026.